A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects With Relapsed or Refractory Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 04 Mar 2015
At a glance
- Drugs CLR 1404 I-131 (Primary)
- Indications Advanced breast cancer; Colon cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Soft tissue sarcoma
- Focus Adverse reactions; Proof of concept
- Sponsors Cellectar Biosciences
- 23 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Nov 2013 Planned end date changed from 1 Dec 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History